

## H1000.H15B Lot No. HC5-9

Cryopreserved Human Hepatocytes Human, Male, Individual

Assured Minimum Yield: 4.0 x 10<sup>6</sup> cells per vial

Viability: 78.4%

Yield and viability are based on experiments performed at XenoTech using XenoTech's thawing protocol and K2000 Hepatocyte Isolation Kit.

Enzyme	Marker Substrate Reaction	[S] (µM)	Rate (pmol/million cells/min)
CYP1A2	Phenacetin O-dealkylation	100	24.5 ± 1.9
CYP2A6	Coumarin 7-hydroxylation	50	40.1 ± 2.6
CYP2B6	Bupropion hydroxylation	500	48.7 ± 5.2
CYP2C8	Amodiaquine N-dealkylation	20	215 ± 56
CYP2C9	Diclofenac 4'-hydroxylation	100	$342 \pm 30$
CYP2C19	S-Mephenytoin 4'-hydroxylation	400	2.17 ± 0.14
CYP2D6	Dextromethorphan O-demethylation	80	13.5 ± 1.2
CYP2E1	Chlorzoxazone 6-hydroxylation	500	122 ± 17
CYP3A4/5	Testosterone 6β-hydroxylation	250	118 ± 7
CYP3A4/5	Midazolam 1'-hydroxylation	30	64.6 ± 11.6
CYP4A/11	Lauric Acid 12-hydroxylation	100	63.7 ± 3.5
UGT	7-Hydroxycoumarin glucuronidation	100	493 ± 26
SULT	7-Hydroxycoumarin sulfonation	100	29.6 ± 3.3

Values for enzyme activities were determined at a single substrate concentration and are mean ± standard deviation of three or more determinations.

To measure cytochrome P450 (CYP), UDP-glucuronosyl transferase (UGT) and sulfotransferase (SULT) activities, hepatocytes (1 x  $10^6$  /mL) in suspension were incubated in triplicate at  $37 \pm 1^{\circ}$ C for 30 minutes in Krebs-Henseleit buffer and marker substrate, at the final concentrations indicated. Metabolite formation was determined by validated LC-MS/MS methods with deuterated metabolites as internal standards.

## **Donor Information**

Gender: Male Age: 30 years of age Race: Caucasian Cause of Death: Cerebrovascular accident Cytomegalovirus (CMV): Positive **Human Immunodeficiency Virus (HIV):** Negative **Hepatitis B Surface Antigen (HbsAg):** Negative **Antibody to Hepatitis C Virus (HCV):** Negative



## Store in liquid nitrogen, vapor phase

CAUTION: This sample should be considered as a potential biohazard and universal precautions should be followed. Intended for *in vitro* use only.

These data were generated by and are the property of XenoTech. These data are not to be reproduced, published or distributed without the express written consent of XenoTech.

Datasheet prepared 24 February 2014